# Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT00549679** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 104 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK256066
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00549679
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-04
- **Primary completion:** 2008-12-15
- **Final completion:** 2008-12-15
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549679, "Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00549679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*